Today: 3 February 2026
Subscribe
Browse Category

NASDAQ:OMER News 24 December 2025 - 25 December 2025

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

December 25, 2025 — Omeros Corporation (NASDAQ: OMER) is having the kind of week biotech investors daydream about: a long-awaited U.S. regulatory win, a sharp stock re-rating, and a sudden pivot from “development-stage hope” to “commercial-stage execution.” The spark was the U.S. FDA approval of YARTEMLEA® (narsoplimab-wuug) as the first and only therapy indicated for hematopoietic stem cell transplant–associated thrombotic…
25 December 2025
·····
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros Corporation (NASDAQ: OMER) is ending Christmas Eve 2025 as one of the market’s most volatile and news-driven movers after the U.S. Food and Drug Administration approved the company’s first commercial product — a moment investors have waited years to see. As of 2:35 p.m. ET in after-hours trading on Wednesday, Dec. 24, 2025, OMER stock traded around $15.36, up…
24 December 2025
·····

Stock Market Today

  • Enact Holdings Q4 CY2025 Revenue Misses Estimates Despite Profit Beat
    February 3, 2026, 5:30 PM EST. Enact Holdings (NASDAQ:ACT), a mortgage insurance provider, reported Q4 CY2025 revenue of $312.7 million, a 1.2% year-on-year increase but below analysts' estimates of $315.7 million. The company posted a non-GAAP profit of $1.23 per share, beating estimates by 11.9%. Pre-tax profit reached $223.1 million, with a 71.3% margin. Book value per share grew 14.8% to $37.66. CEO Rohit Gupta highlighted the quarter as strong, citing disciplined execution and credit performance. Enact primarily earns via insurance premiums, which composed 82.7% of revenue over five years. Despite a 3.4% annualized revenue growth over two years, the slower increase and revenue miss raised concerns. The company supports first-time homebuyers by providing private mortgage insurance enabling lower down payments.
Go toTop